Vertex and AbCellera Partner on Autoimmune TCEs Amid Diverging Financial Trajectories
Vertex Pharmaceuticals funds AbCellera’s discovery efforts with $28 million upfront payment as both firms navigate distinct market realities.
AbCellera Biologics and Vertex Pharmaceuticals announced a strategic collaboration on July 29 to research, develop, and commercialise multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will lead the discovery phase using its proprietary platform, while Vertex will fund all research and development activities and retain commercialisation rights. AbCellera received an upfront payment of $28 million and is eligible for future preclinical, regulatory, and commercial milestone payments, as well as tiered royalties on net sales.
The partnership underscores the contrasting financial positions of the two entities. Vertex is operating from a position of significant strength, reporting second-quarter 2026 total revenues of $3.33 billion, a 12 per cent year-on-year increase, alongside a net income of $1.1 billion. This growth is driven by its dominant cystic fibrosis portfolio and emerging contributions from therapies such as CASGEVY and JOURNAVX. Consequently, Vertex raised its full-year 2026 revenue guidance to a range of $13.1 billion to $13.2 billion.
In contrast, AbCellera remains a clinical-stage entity reliant on partnerships. The company reported second-quarter 2026 revenue of $4.1 million, down from $17.1 million a year earlier, resulting in a net loss of $55.4 million. AbCellera’s quarterly research and development spend stands at $46.0 million, highlighting its dependence on upfront cash and future milestones to offset operational costs.
Despite the current losses, AbCellera maintains strong liquidity with $540.1 million in cash and marketable securities. On August 10, the company announced that the Phase 2 portion of its Phase 1/2 trial for ABCL635, an investigational treatment for menopausal hot flashes, met its primary efficacy endpoints. Following this data, JonesResearch upgraded AbCellera’s price target from $13 to $25, maintaining a Buy rating.
Institutional interest in both companies has shifted in the first quarter of 2026. Hedge fund backing for Vertex increased from 64 funds in the fourth quarter of 2025 to 68 in the first quarter of 2026. AbCellera’s support dropped slightly from 22 to 20 funds over the same period, though some investors adjusted their positions, with Walleye Capital increasing its stake by 8 per cent.
The deal follows a broader industry trend of commercial pharmaceutical leaders leveraging platform technologies from clinical-stage developers. Similar arrangements have been observed in the oncology sector, such as the partnership between Biohaven and Regeneron, where established players provide capital and commercial infrastructure in exchange for access to innovative discovery platforms.
